For this purpose, we analyzed both total cFGF23 and bioactive iFGF23, biomarkers of iron metabolism, including hepcidin, inflammation, and EPO, in a cohort of non-dialysis CKD patients with predominantly moderate to severe renal function impairment (median eGFR 30 mL/min./1.73m2). This evidence concerns the gene EPO and chronic kidney disease.